Swine Influenza

Phase 1Biologic

Novartis

Swine Influenza is one of 5 biologic programs targeting Swine Influenza. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Swine InfluenzaActive, not recruiting

Swine InfluenzaPhase 1

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Swine Influenza

#DrugCompanyPhaseTrials

Crestor

Fluzone

Tamiflu

CConrado Roberto Hoffmann Filho

Phase 3

1 4

Relenza

GGlaxo Dba Glaxosmithkline

Phase 3

1 5

Swine Influenza

Novartis

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Swine Influenza1 trial

Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.

Completed· Novartis logo

Novartis·Phase 1·NCT01855945·627 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Swine Influenza. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Swine Influenza compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Swine Influenza. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: Novartis

Swine Influenza

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Swine Influenza1 trial

References

Drug Info

Quick Facts

Related News